2019-nCoV Spike protein S1  (∆Y145, ∆H146, E484K, D614G) (C19S1-G231DH)

2019-nCoV Spike protein S1 (∆Y145, ∆H146, E484K, D614G) (C19S1-G231DH)

  • $100.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description: Recombinant 2019-nCoV Spike protein S1 (∆Y145, ∆H146, E484K, D614G) (16-685) was expressed in CHO cells using a C-terminal His- tag.

Species: SARS-CoV-2

Tag: HIS tag

Expression System: CHO Cells

Sequence: 16-685

Genbank Number: MN908947

Purity: Sample Purity Data. For specific information on a given lot, see the related technical datasheet.

Storage, Stability, and Shipping: Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Molecular Weight:  76 kDa

Gene Aliases : 2019-nCoV s1, SARS-CoV-2 spike S1, SARS-CoV-2 S1, novel coronavirus spike s1, nCoV spike s1, coronavirus spike S1.

Scientific Background: Novel coronavirus SARS-CoV-2 has caused the pandemic of the respiratory diseases (COVID-19) around the world since 2020 (1). The spike glycoprotein (S) of coronavirus, a type I transmembrane protein containing two subunits, S1 and S2 is known to bind with host cells through the interaction with angiotensin-converting enzyme 2 (ACE2) and facilitate viral entry into the host cell (2). Highly transmissible B.1.617 variant identified in India has mutations (∆Y145, ∆H146, E484K, D614G) in the spike protein. These mutations may result in increased transmissibility and re-infection or resistance to vaccine-elicited antibody.  As new variants emerge, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (3).

References : 

  1. Zhou P, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-89.
  2. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. Nature. 2020, 581:215-220.
  3. Takuya T, et al: The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies. 2021. doi: https://doi.org/10.1101/2021.05.14.444076

Product Sheets (By Lot #) :

J3978-6